Today's journal articles

Trastuzumab-Induced Cardiotoxicity: Clinical and Prognostic Implications of Troponin I Evaluation.

Triple therapy with olmesartan medoxomil, amlodipine besylate, and hydrochlorothiazide in adult patients with hypertension: The TRINITY multicenter, randomized, double-blind, 12-week, parallel-group study.

Do you need further information on any of the agents being evaluated in the trial(s) below?  Let us know...

New Clinical Trials

No clinical trials today

Previous Journal Entries

VEGF pathway inhibition by anticancer agent sunitinib and susceptibility to atherosclerosis plaque disruption.

Pyrrolo[1,2 - a]pyrazine and pyrazolo[1,5 - a]pyrazine: Novel, potent, and selective series of Vasopressin(1b) receptor antagonists.

LASSBio-294, A Compound With Inotropic and Lusitropic Activity, Decreases Cardiac Remodeling and Improves Ca(2+) Influx Into Sarcoplasmic Reticulum After Myocardial Infarction.

Randomized Comparison of Eptifibatide Versus Abciximab in Primary Percutaneous Coronary Intervention in Patients With Acute ST-Segment Elevation Myocardial Infarction Results of the EVA-AMI Trial.

Eptifibatide Is Noninferior to Abciximab in Primary Percutaneous Coronary Intervention Results From the SCAAR (Swedish Coronary Angiography and Angioplasty Registry).

Comparison of Atorvastatin 80 mg/day Versus Simvastatin 20 to 40 mg/day on Frequency of Cardiovascular Events Late (Five Years) After Acute Myocardial Infarction (from the Incremental Decrease in End Points Through Aggressive Lipid Lowering [IDEAL] Trial).

Effects of Add-on Fluvastatin Therapy in Patients with Chronic Proteinuric Nephropathy on Dual Renin-Angiotensin System Blockade: The ESPLANADE Trial.

Selexipag: a selective prostacyclin receptor agonist that does not affect rat gastric function.

Short- and Long-Term Outcomes of Coronary Artery Bypass Grafting or Drug-Eluting Stent Implantation for Multivessel Coronary Artery Disease in Patients With Chronic Kidney Disease.

Extended-Duration Venous Thromboembolism Prophylaxis in Acutely Ill Medical Patients With Recently Reduced Mobility: A Randomized Trial.

Impact of Multivessel Coronary Artery Disease and Noninfarct-Related Artery Revascularization on Outcome of Patients With ST-Elevation Myocardial Infarction Transferred for Primary Percutaneous Coronary Intervention (from the EUROTRANSFER Registry).

Dilation of Epicardial Coronary Arteries by the G Protein-Coupled Estrogen Receptor Agonists G-1 and ICI 182,780.

Effect of Ezetimibe Monotherapy on Lipid Metabolism and Arterial Stiffness Assessed by Cardio-Ankle Vascular Index in Type 2 Diabetic Patients.

Iloprost-Induced Nociception: Determination of the Site of Anti-nociceptive Action of Cyclooxygenase Inhibitors and the Involvement of Cyclooxygenase Products in Central Mechanisms of Nociception.

Relationship Between Nonsustained Ventricular Tachycardia After Non-ST-Elevation Acute Coronary Syndrome and Sudden Cardiac Death. Observations From the Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST-Elevation Acute Coronary Syndrome-Thrombolysis in Myocardial Infarction 36 (MERLIN-TIMI 36) Randomized Controlled Trial.

Effects of Sulfaphenazole Derivatives on Cardiac Ischemia-Reperfusion Injury: Association of Cytochrome P450 Activity and Infarct Size.

Synthesis and biological evaluation of oxazole derivatives as T - type calcium channel blockers.

Dipyridamole with Low-Dose Aspirin Augments the Infarct Size-Limiting Effects of Simvastatin.

FAD286, an aldosterone synthase inhibitor, reduced atherosclerosis and inflammation in apolipoprotein E-deficient mice.

Sustained release of VEGF through PLGA microparticles improves vasculogenesis and tissue remodeling in an acute myocardial ischemia-reperfusion model.

Today's News Items

Sangart, Inc. Reports Positive Phase IIa Data for Novel Oxygen Therapeutic Agent MP4OX in Sever Trauma Patients - Study Meets Primary Endpoint of Reducing Lactate Levels in Trauma Patients

Training Courses & Meetings

No events listed

Previous News Items

Genetic substudy shows fewer major cardiovascular events with ticagrelor (brilinta) regardless of relevant genetic variability in ACS patients

Combination therapy of telmisartan and amlodipine provides significantly better blood pressure lowering than either agent alone

A new era for patients with atrial fibrillation - Dabigatran etexilate at the forefront

Portola Pharmaceuticals Announces that Phase 2 INNOVATE-PCI Trial with Elinogrel Achieved Objectives

Multaq® First-line Option in New 2010 ESC Guidelines for the Management of Atrial Fibrillation

Bionovo Receives Positive Guidance from FDA on Menerba

---

For faster discovery, automatically organize PubMed results into categories